Enclomiphene Citrate vs Testosterone Enanthate: Real-World Evidence Comparison

How Each Drug Raises Testosterone

Enclomiphene citrate and testosterone enanthate both raise circulating testosterone, but through entirely different pathways. Understanding the mechanism is not optional background information. It determines which patients respond, which labs to track, and what happens if you stop the drug.

Enclomiphene: Working With the Axis

Enclomiphene is the trans-isomer of clomiphene. It binds estrogen receptors in the hypothalamus and pituitary, blocking negative feedback from estradiol. The pituitary then secretes more LH and FSH. LH stimulates Leydig cells to synthesize testosterone. FSH drives spermatogenesis. The testes remain active throughout treatment.

In a randomized controlled trial by Kim et al. (BJU Int 2016, N=136), 12 weeks of enclomiphene 12.5 mg or 25 mg daily raised mean serum testosterone from roughly 230 ng/dL to 400 to 450 ng/dL while preserving sperm counts, a finding not replicated with exogenous testosterone at any dose 1. LH and FSH rose in parallel, confirming intact hypothalamic-pituitary function.

Testosterone Enanthate: Replacing From Outside

Testosterone enanthate is esterified testosterone dissolved in oil. After intramuscular or subcutaneous injection, esterases cleave the enanthate side chain, releasing free testosterone over 7 to 10 days. Serum T peaks at 24 to 72 hours and troughs before the next dose 2.

Because circulating testosterone rises sharply, the hypothalamus and pituitary reduce GnRH, LH, and FSH output. Within 4 to 6 weeks of standard dosing (100 to 200 mg every 1 to 2 weeks), LH and FSH typically fall to <1 mIU/mL. The testes atrophy moderately and stop producing meaningful amounts of endogenous testosterone or sperm.

What the Mechanistic Difference Means Clinically

A patient who still produces some LH and FSH (secondary or functional hypogonadism) may respond well to enclomiphene. A patient with primary testicular failure (elevated LH already, low testosterone) will not respond to a SERM because the Leydig cells cannot increase output even when stimulated. Testosterone enanthate bypasses the axis entirely and works in both primary and secondary hypogonadism.

Trial Evidence and Real-World Data

The Kim et al. 2016 Trial

The most cited randomized trial comparing a clomiphene-class agent directly against exogenous testosterone is Kim et al. (BJU Int 2016) 1. This 12-week RCT (N=136 men with secondary hypogonadism, mean age 33, mean baseline T 230 ng/dL) assigned participants to enclomiphene 12.5 mg, enclomiphene 25 mg, or testosterone gel 1.62%. Key findings:

• All three arms raised serum testosterone to the normal range (300 to 1,000 ng/dL).
• Sperm concentration fell 22% in the testosterone gel arm and rose 18% in both enclomiphene arms.
• Sexual function scores (IIEF) improved comparably across all groups at 12 weeks.
• Testosterone gel produced slightly higher mean T levels (510 ng/dL) than enclomiphene 12.5 mg (400 ng/dL).

Testosterone enanthate was not the active comparator in this specific trial; the exogenous arm used topical testosterone. Extrapolating to TE is pharmacologically reasonable because the endpoint (HPG axis suppression vs. Preservation) reflects the class effect of exogenous testosterone, not the delivery route.

The T-Trials (NEJM 2016)

The Testosterone Trials (T-Trials) enrolled 790 men aged 65 or older with a serum testosterone below 275 ng/dL and at least one symptom domain 2. Participants received testosterone gel (1%) or placebo for 12 months. The sexual function trial showed a mean testosterone rise to approximately 454 ng/dL in the treatment arm vs. 230 ng/dL in placebo (P<0.001). Sexual desire, erectile function, and walking distance all improved significantly. The T-Trials did not include a SERM arm, so they do not directly answer the enclomiphene-vs-TE question, but they establish strong evidence for the clinical benefits of normalizing testosterone in symptomatic older men.

Testosterone enanthate at 100 to 200 mg every 7 to 14 days produces pharmacokinetic profiles that achieve comparable mean serum levels to the gels used in T-Trials, with higher peak-to-trough variability 2.

Real-World Prescribing Patterns

Enclomiphene remains off-label in the United States following the FDA's 2013 and 2014 Complete Response Letters to Repros Therapeutics. Despite this, it is widely prescribed through compounding pharmacies. A 2022 analysis of US outpatient TRT prescriptions found that oral agents (primarily clomiphene and enclomiphene) accounted for roughly 12% of new male hypogonadism starts, with the injectable testosterone segment holding approximately 52% of the market 3.

Testosterone enanthate specifically benefits from an FDA-approved label, established long-term safety data exceeding 60 years of clinical use, and a cost structure that makes it among the least expensive TRT options, often under $30 per month with generic formulations available through most pharmacies 4.

Efficacy: Testosterone Levels, Symptoms, and Sexual Function

Serum Testosterone Targets

Both drugs can achieve serum total testosterone in the 400 to 700 ng/dL range when dosed appropriately. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism recommends a target of 400 to 700 ng/dL for most men on TRT, measured as a morning trough 5.

Testosterone enanthate at 100 mg weekly produces a trough of approximately 450 to 550 ng/dL and a peak near 900 to 1,100 ng/dL. The peak-trough swing is clinically relevant: some patients notice mood or energy changes between injections. Subcutaneous injection of smaller doses (50 to 80 mg twice weekly) flattens the curve and is increasingly preferred in telehealth settings.

Enclomiphene at 25 mg daily raised mean trough T to approximately 450 ng/dL in Kim et al. 1, but individual response varies more than with TE because it depends on pituitary sensitivity and Leydig cell reserve.

Symptom Relief

Sexual function, energy, mood, and body composition improvements appear similar between the two drugs in men with secondary hypogonadism who achieve comparable testosterone levels. The T-Trials demonstrated that sexual desire improved by a mean of 1.2 points on the DISF-SR scale vs. 0.4 for placebo (P<0.001) with normalized testosterone 2. Enclomiphene trials have not yet replicated this in a similarly powered older cohort.

Estradiol Management

Both drugs affect estradiol. Testosterone enanthate converts to estradiol via aromatase; at standard doses, estradiol often rises to 30 to 60 pg/mL. Values above 40 to 50 pg/mL correlate with gynecomastia and water retention in some men. Aromatase inhibitors (anastrozole 0.25 to 0.5 mg twice weekly) are sometimes added.

Enclomiphene raises both testosterone and estradiol because more substrate (testosterone) is available for aromatization. In Kim et al., estradiol rose modestly but remained within range for most participants 1. The drug itself is an estrogen receptor antagonist at the hypothalamus, which partially offsets peripheral estrogenic signals.

Fertility Preservation: The Deciding Factor for Many Men

This section matters most for men under 40 who plan to father children.

Enclomiphene and Spermatogenesis

Sperm production requires both FSH and intratesticular testosterone concentrations far above serum levels (approximately 50 to 100 times higher). Exogenous testosterone suppresses FSH to near zero and drops intratesticular testosterone by 94 to 99%, making conception nearly impossible without concurrent FSH/hCG support 6.

Enclomiphene maintains or raises FSH. In Kim et al., sperm concentration increased from a mean of 26 million/mL to 31 million/mL after 12 weeks on enclomiphene 12.5 mg 1. That 19% rise is clinically meaningful for men near the lower threshold of normal fertility (<15 million/mL per WHO criteria).

Testosterone Enanthate and Fertility

Testosterone enanthate at doses used for hypogonadism (100 to 200 mg weekly) causes azoospermia in approximately 65 to 75% of men within 3 to 6 months 7. Spermatogenesis may recover after stopping TE, but recovery is not guaranteed. Recovery time averages 6 to 18 months and may be incomplete in men who have been on TE for more than 2 years 8.

Men who wish to remain on TE but preserve fertility can add human chorionic gonadotropin (hCG) 500 to 1,000 IU subcutaneously two to three times per week. HCG mimics LH, stimulates Leydig cells, maintains intratesticular testosterone, and partially preserves spermatogenesis, though FSH remains suppressed without adding recombinant FSH 9.

Safety Profile and Adverse Effects

Shared Risks

Both drugs share several class-level risks. Testosterone elevation, regardless of source, raises hematocrit. Polycythemia (hematocrit above 54%) occurred in 5.1% of testosterone-treated men in a meta-analysis of 72 trials (N=6,460) 10. Phlebotomy or dose reduction corrects this in most cases. Both drugs require PSA monitoring in men over 40 because testosterone is a permissive factor in prostate growth.

Risks Specific to Testosterone Enanthate

• Injection-site reactions (pain, induration, rarely abscess) occur in 5 to 10% of users.
• Peak-trough T swings can cause mood lability, irritability near trough, and supraphysiologic peak effects (acne, aggressive behavior) in a minority of patients.
• Erythrocytosis risk is higher with injectables than with transdermal or oral routes because Cmax is higher 10.
• Testicular atrophy is predictable and sometimes distressing to patients aesthetically.

Risks Specific to Enclomiphene

• Visual disturbances (blurred vision, scotomata) have been reported with clomiphene class agents, though less frequently with the pure trans-isomer enclomiphene than with racemic clomiphene 1.
• Mood effects: some men report anxiety or emotional blunting, possibly related to estrogenic signaling changes at central receptors.
• Non-response in primary hypogonadism is not a side effect but a predictable mechanistic failure.
• Long-term safety data beyond 12 months are limited given the off-label status and absence of large phase 3 completion.

Dosing, Administration, and Monitoring

Enclomiphene Protocol

Standard starting dose: 12.5 mg orally once daily. If total testosterone remains below 350 ng/dL at 6 to 8 weeks, titrate to 25 mg daily. Check fasting morning total testosterone, LH, FSH, estradiol, and CBC at baseline, at 6 to 8 weeks, and every 3 to 6 months thereafter. If LH does not rise above baseline, primary hypogonadism is likely and switching to TE should be discussed.

Testosterone Enanthate Protocol

Standard dosing for male hypogonadism per FDA labeling: 50 to 400 mg every 2 to 4 weeks 4. Most telehealth and specialty endocrinology practices now use 100 mg weekly or 200 mg every 2 weeks, with subcutaneous administration increasingly preferred for ease and reduced pain. Monitor total testosterone (trough, drawn just before the next dose), hematocrit, PSA, and lipids at 3 months, then every 6 months once stable.

The Endocrine Society guideline states: "We suggest monitoring testosterone levels 3 to 6 months after initiating treatment to ensure levels are within the normal range" 5.

Switching From Enclomiphene to Testosterone Enanthate

Patients switch for several reasons: insufficient testosterone response on enclomiphene, discovery of primary hypogonadism, change in fertility plans, or preference for more consistent hormone levels.

When to Switch

Consider switching when any of the following apply after 8 to 12 weeks of enclomiphene at 25 mg daily:

1. Total testosterone remains below 350 ng/dL.
2. LH did not rise at all, suggesting pituitary dysfunction rather than simple hypothalamic feedback failure.
3. Symptom burden (fatigue, libido, erections) has not improved despite adequate testosterone levels, pointing to a possible androgenic receptor or other etiology.
4. The patient has decided against future fertility and wants a more predictable pharmacokinetic profile.

Transition Protocol

No washout is strictly required. Enclomiphene has a half-life of approximately 10 days for the trans-isomer. Starting TE on the same day as stopping enclomiphene prevents a gap in testosterone coverage. Recheck serum T and LH at 6 weeks after starting TE to confirm suppression and appropriate dosing. The patient should be counseled that LH and FSH will suppress within 3 to 6 weeks and that fertility will decline during this period.

The HealthRX clinical team uses the following decision framework internally:

Step 1. Confirm diagnosis with two fasting morning total testosterone readings below 300 ng/dL plus clinical symptoms per the Endocrine Society guideline 5.

Step 2. Measure LH and FSH. If LH is low or normal with low T, secondary hypogonadism is confirmed and enclomiphene is a reasonable first-line option. If LH is elevated, primary hypogonadism is present and TE is indicated from the start.

Step 3. Discuss fertility. If the patient plans conception within 2 years, start enclomiphene. If fertility is not a near-term goal, either option is appropriate; patient preference for route of administration often decides.

Step 4. Reassess at 8 weeks. Non-responders to enclomiphene (T still below 350 ng/dL, no LH rise) transition to TE.

Step 5. Once on TE, offer hCG add-on if fertility goals change.

Cost and Access

Testosterone enanthate is generically available and FDA-approved. Cash-pay costs at most pharmacies range from $20 to $50 per month for 100 to 200 mg weekly dosing. It is covered by most insurance plans with a diagnosis of hypogonadism.

Enclomiphene is available through compounding pharmacies at roughly $60 to $120 per month. Insurance coverage is rare given the off-label status. Racemic clomiphene citrate (FDA-approved for female infertility, commonly prescribed off-label in men) costs $10 to $30 per month and has a longer evidence base in male hypogonadism, though it carries more estrogenic side-effect potential than pure enclomiphene 11.

Who Should Choose Which Drug

Men with secondary hypogonadism who are actively trying to conceive, or who want to preserve fertility as an option, are the clearest candidates for enclomiphene. The mechanism is well-matched: the problem is inadequate hypothalamic signaling, and enclomiphene corrects it at the source.

Men with primary hypogonadism have failed Leydig cells that cannot respond to more LH. Testosterone enanthate is the indicated choice. The same applies to men who have tried enclomiphene and not responded, or men who prioritize consistent hormone levels and do not mind weekly injections.

Age and comorbidities matter too. Older men (>65) in the T-Trials showed meaningful benefits from testosterone normalization across sexual function, physical performance, and bone mineral density 2. Enclomiphene has not been studied at scale in this population.

Check total testosterone 6 weeks after starting either drug, and adjust dose to keep the morning trough in the 400 to 700 ng/dL range per the Endocrine Society 2018 guideline 5.